A pharmaceutical composition for the prevention or treatment of coronavirus infection containing a cell-penetrating peptide-nucleic acid oligomer as an active ingredient.

Abstract

This invention provides PNA oligomers containing modified PNA for the prevention or treatment of coronavirus infections. The PNA oligomers of this invention can be delivered into virus-infected cells without the use of a delivery carrier and can suppress viral replication. Therefore, they do not have the side effects of delivery carriers used to increase cell permeability in conventional drugs, and because they have high binding affinity to the target, they can bind to the target and suppress viral replication even in the event of mismatch. Accordingly, they are expected to be used as effective coronavirus treatments that can cope with rapidly mutating viral infections.